Literature DB >> 15808808

Low renin hypertensive states: perspectives, unsolved problems, future research.

Richard D Gordon1, John H Laragh, John W Funder.   

Abstract

Some causes of low renin hypertension are familial with known genetic bases. One of them, primary aldosteronism, is specifically treatable by mineralocorticoid receptor blockers or by surgery, and has at least two different familial varieties. These have provided insights into its natural history, with long normotensive and normokalemic phases, and variable expression within the same family. Primary aldosteronism was considered rare, but recent work beginning in 1992 suggests that it might be the most common curable cause of hypertension, worth screening for in every hypertensive. Evidence is now compelling that inappropriate aldosterone for salt status can cause not only hypertension, but vascular inflammation and end-organ damage, preventable by mineralocorticoid receptor blockade.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15808808     DOI: 10.1016/j.tem.2005.02.004

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  8 in total

Review 1.  Hypertension due to loss of clock: novel insight from the molecular analysis of Cry1/Cry2-deleted mice.

Authors:  Hitoshi Okamura; Masao Doi; Yoshiaki Yamaguchi; Jean-Michel Fustin
Journal:  Curr Hypertens Rep       Date:  2011-04       Impact factor: 5.369

2.  Walz aldosteronoma.

Authors:  Elizabeth G Grubbs; Jeffrey E Lee
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

3.  Adrenal Tissue-Specific Deletion of TASK Channels Causes Aldosterone-Driven Angiotensin II-Independent Hypertension.

Authors:  Nick A Guagliardo; Junlan Yao; Eric J Stipes; Sylvia Cechova; Thu H Le; Douglas A Bayliss; David T Breault; Paula Q Barrett
Journal:  Hypertension       Date:  2019-02       Impact factor: 10.190

4.  TASK-3 channel deletion in mice recapitulates low-renin essential hypertension.

Authors:  Nick A Guagliardo; Junlan Yao; Changlong Hu; Elaine M Schertz; David A Tyson; Robert M Carey; Douglas A Bayliss; Paula Q Barrett
Journal:  Hypertension       Date:  2012-04-09       Impact factor: 10.190

5.  Plasma sodium stiffens vascular endothelium and reduces nitric oxide release.

Authors:  Hans Oberleithner; Christoph Riethmüller; Hermann Schillers; Graham A MacGregor; Hugh E de Wardener; Martin Hausberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-02       Impact factor: 11.205

6.  AT1 receptors prevent salt-induced vascular dysfunction in isolated middle cerebral arteries of 2 kidney-1 clip hypertensive rats.

Authors:  Andreas M Beyer; Katherine Fredrich; Julian H Lombard
Journal:  Am J Hypertens       Date:  2013-08-09       Impact factor: 2.689

7.  Gain-of-function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice.

Authors:  Sandrine Billet; Sabine Bardin; Sonia Verp; Véronique Baudrie; Annie Michaud; Sophie Conchon; Martine Muffat-Joly; Brigitte Escoubet; Evelyne Souil; Ghislaine Hamard; Kenneth E Bernstein; Jean Marie Gasc; Jean-Luc Elghozi; Pierre Corvol; Eric Clauser
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

8.  Clinical Characteristics of Target Organ Damage in Primary Aldosteronism with or without Metabolic Syndrome.

Authors:  Xiaona Bu; Fang Sun; Hexuan Zhang; Xiaoli Liu; Zhigang Zhao; Hongbo He; Yingsha Li; Zhencheng Yan; Zhiming Zhu
Journal:  J Diabetes Res       Date:  2022-09-07       Impact factor: 4.061

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.